Screening for lung cancer

Are we there yet?

Maurizio V. Infante, Jesper H. Pedersen

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose of review: In lung cancer screening with low-dose spiral computed tomography (LDCT), the proportion of stage I disease is 50-85%, and the survival rate for resected stage I disease can exceed 90%, but proof of real benefit in terms of lung cancer mortality reduction must come from the several randomized trials underway in Europe and in the USA. Our purpose is to update the readers on recent progress in medical knowledge in this field. Recent findings: Relevant novelties regarding technical and collateral aspects of lung cancer screening have been made available, covering the performance of detection systems and nodule evaluation protocols, means to increase cost-effectiveness, insight into the biology of lung cancer, promotion of minimally invasive and lung-sparing surgical options, effects of screening on smoking habits and early follow-up findings in one randomized trial of LDCT vs. clinical review. CONCLUSION: Early follow-up data suggest that the effect of screening with LDCT on mortality might be smaller than expected, but definitive follow-up data are still awaited from all ongoing randomized trials. Lung cancer screening research is yielding a relevant body of medical knowledge that will be beneficial for other smoking-related diseases and contribute to a better understanding of lung cancer biology.

Original languageEnglish
Pages (from-to)301-306
Number of pages6
JournalCurrent Opinion in Pulmonary Medicine
Volume16
Issue number4
DOIs
Publication statusPublished - Jul 2010

Fingerprint

Lung Neoplasms
Spiral Computed Tomography
Early Detection of Cancer
Smoking
Mortality
Habits
Cost-Benefit Analysis
Survival Rate
Lung
Research

Keywords

  • Low-dose computed tomography
  • Lung cancer
  • Randomized controlled trial
  • Screening

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Screening for lung cancer : Are we there yet? / Infante, Maurizio V.; Pedersen, Jesper H.

In: Current Opinion in Pulmonary Medicine, Vol. 16, No. 4, 07.2010, p. 301-306.

Research output: Contribution to journalArticle

Infante, Maurizio V. ; Pedersen, Jesper H. / Screening for lung cancer : Are we there yet?. In: Current Opinion in Pulmonary Medicine. 2010 ; Vol. 16, No. 4. pp. 301-306.
@article{76c65474df9e44d09658e6dbdb9b2719,
title = "Screening for lung cancer: Are we there yet?",
abstract = "Purpose of review: In lung cancer screening with low-dose spiral computed tomography (LDCT), the proportion of stage I disease is 50-85{\%}, and the survival rate for resected stage I disease can exceed 90{\%}, but proof of real benefit in terms of lung cancer mortality reduction must come from the several randomized trials underway in Europe and in the USA. Our purpose is to update the readers on recent progress in medical knowledge in this field. Recent findings: Relevant novelties regarding technical and collateral aspects of lung cancer screening have been made available, covering the performance of detection systems and nodule evaluation protocols, means to increase cost-effectiveness, insight into the biology of lung cancer, promotion of minimally invasive and lung-sparing surgical options, effects of screening on smoking habits and early follow-up findings in one randomized trial of LDCT vs. clinical review. CONCLUSION: Early follow-up data suggest that the effect of screening with LDCT on mortality might be smaller than expected, but definitive follow-up data are still awaited from all ongoing randomized trials. Lung cancer screening research is yielding a relevant body of medical knowledge that will be beneficial for other smoking-related diseases and contribute to a better understanding of lung cancer biology.",
keywords = "Low-dose computed tomography, Lung cancer, Randomized controlled trial, Screening",
author = "Infante, {Maurizio V.} and Pedersen, {Jesper H.}",
year = "2010",
month = "7",
doi = "10.1097/MCP.0b013e32833aa01c",
language = "English",
volume = "16",
pages = "301--306",
journal = "Current Opinion in Pulmonary Medicine",
issn = "1070-5287",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Screening for lung cancer

T2 - Are we there yet?

AU - Infante, Maurizio V.

AU - Pedersen, Jesper H.

PY - 2010/7

Y1 - 2010/7

N2 - Purpose of review: In lung cancer screening with low-dose spiral computed tomography (LDCT), the proportion of stage I disease is 50-85%, and the survival rate for resected stage I disease can exceed 90%, but proof of real benefit in terms of lung cancer mortality reduction must come from the several randomized trials underway in Europe and in the USA. Our purpose is to update the readers on recent progress in medical knowledge in this field. Recent findings: Relevant novelties regarding technical and collateral aspects of lung cancer screening have been made available, covering the performance of detection systems and nodule evaluation protocols, means to increase cost-effectiveness, insight into the biology of lung cancer, promotion of minimally invasive and lung-sparing surgical options, effects of screening on smoking habits and early follow-up findings in one randomized trial of LDCT vs. clinical review. CONCLUSION: Early follow-up data suggest that the effect of screening with LDCT on mortality might be smaller than expected, but definitive follow-up data are still awaited from all ongoing randomized trials. Lung cancer screening research is yielding a relevant body of medical knowledge that will be beneficial for other smoking-related diseases and contribute to a better understanding of lung cancer biology.

AB - Purpose of review: In lung cancer screening with low-dose spiral computed tomography (LDCT), the proportion of stage I disease is 50-85%, and the survival rate for resected stage I disease can exceed 90%, but proof of real benefit in terms of lung cancer mortality reduction must come from the several randomized trials underway in Europe and in the USA. Our purpose is to update the readers on recent progress in medical knowledge in this field. Recent findings: Relevant novelties regarding technical and collateral aspects of lung cancer screening have been made available, covering the performance of detection systems and nodule evaluation protocols, means to increase cost-effectiveness, insight into the biology of lung cancer, promotion of minimally invasive and lung-sparing surgical options, effects of screening on smoking habits and early follow-up findings in one randomized trial of LDCT vs. clinical review. CONCLUSION: Early follow-up data suggest that the effect of screening with LDCT on mortality might be smaller than expected, but definitive follow-up data are still awaited from all ongoing randomized trials. Lung cancer screening research is yielding a relevant body of medical knowledge that will be beneficial for other smoking-related diseases and contribute to a better understanding of lung cancer biology.

KW - Low-dose computed tomography

KW - Lung cancer

KW - Randomized controlled trial

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=77953652117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953652117&partnerID=8YFLogxK

U2 - 10.1097/MCP.0b013e32833aa01c

DO - 10.1097/MCP.0b013e32833aa01c

M3 - Article

VL - 16

SP - 301

EP - 306

JO - Current Opinion in Pulmonary Medicine

JF - Current Opinion in Pulmonary Medicine

SN - 1070-5287

IS - 4

ER -